Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Glowing dye could help lung cancer patients keep more healthy lung tissue

NCT ID NCT02570815

First seen Feb 02, 2026 · Last updated Jun 22, 2026 · Updated 20 times

Summary

This study tests whether a dye called indocyanine green (ICG) can help surgeons see the exact boundary of a lung cancer tumor during robotic surgery. The dye makes the healthy lung glow, leaving the cancerous segment dark. The surgeon then removes only that dark segment, sparing more healthy tissue. The trial involves 250 adults with early-stage non-small cell lung cancer and aims to see if this technique is accurate and safe.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • St. Joseph's Healthcare Hamilton

    RECRUITING

    Hamilton, Ontario, L8N 4A6, Canada

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

indocyanine green (ICG) dye

What this could lead to

If successful, this technique could allow more patients with early lung cancer to have a smaller, lung-sparing surgery instead of removing an entire lobe.

What could go wrong

This is an early Phase 1 trial focused on feasibility, not yet on long-term outcomes. The dye may cause allergic reactions, and the approach may not work for all patients.

Conditions

The condition(s) this trial relates to.

lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.